Tonix Pharmaceuticals Holding Corp. (NASDAQ: TNXP) announced a poster presentation at ISPOR 2026, highlighting findings from a retrospective cohort study that analyzed U.S. claims data from adults with fibromyalgia between April 2021 and April 2024. The presentation will feature real-world insights related to fibromyalgia treatment, following the FDA approval of TONMYA (cyclobenzaprine HCl sublingual tablets 2.8mg) in August 2025 and its subsequent U.S. commercial launch in November 2025. This research is significant as TONMYA is the first new treatment for fibromyalgia in over 15 years, addressing a high unmet medical need.
The study, which leverages real-world data, aims to provide a deeper understanding of treatment patterns and patient outcomes in fibromyalgia. By analyzing claims data, Tonix seeks to demonstrate the real-world effectiveness of TONMYA and its impact on patients, potentially supporting broader adoption among healthcare providers. The presentation at ISPOR 2026, a leading conference for health economics and outcomes research, underscores the company's commitment to evidence-based medicine and post-marketing surveillance.
Tonix Pharmaceuticals is a fully-integrated, commercial-stage biotechnology company focused on central nervous system (CNS) and immunology treatments. TONMYA, its flagship medicine, is the first new treatment for fibromyalgia in more than 15 years. The company's CNS commercial infrastructure also supports its acute migraine products, including Zembrace SymTouch and Tosymra. Tonix is further exploring the potential of TONMYA in Phase 2 clinical trials for major depressive disorder and acute stress disorder. Additionally, its CNS pipeline includes TNX-2900, which is Phase 2 ready for Prader-Willi syndrome, a rare disease. The company is also advancing immunology programs, such as monoclonal antibody TNX-4800 for Lyme disease prophylaxis and TNX-1500, a third-generation CD40 ligand inhibitor for kidney transplant rejection prevention.
The real-world data presentation at ISPOR 2026 is expected to provide valuable insights into fibromyalgia treatment patterns and outcomes, potentially influencing clinical practice and payer decisions. For more details, the full press release is available at https://ibn.fm/A3668. The latest news and updates relating to TNXP are available in the company's newsroom at https://ibn.fm/TNXP.
This announcement is particularly important for investors and healthcare professionals, as it demonstrates Tonix's proactive approach to generating real-world evidence for TONMYA. The data could support the drug's positioning in a competitive market and provide insights into its long-term value. As the first new fibromyalgia treatment in over a decade, TONMYA has the potential to significantly improve patient care, and this research will help validate its real-world impact.